News
Gilead to acquire German Phenex’s FXR programme for liver diseases
US-based Gilead Sciences has entered into an agreement with German Phenex Pharmaceuticals to acquire its Farnesoid X Receptor (FXR) programme, including small molecule FXR...
Press Releases
Eli Lilly acquires Novartis Animal Health for $5.4bn
US-based Eli Lilly and Company has completed the acquisition of Novartis Animal Health for $5.4bn. Lilly noted the acquisition was funded...
Research Insight
Amgen and Kite Pharma to develop CAR T cell immunotherapies
US-based Amgen has signed a strategic research collaboration and license agreement with Kite Pharma to develop and commercialise chimeric antigen receptor (CAR) T cell...
Press Releases
TxCell and Ferring collaboration with lead product Ovasave(R) to receive additional development expertise from Trizell
TxCell SA (FR0010127662 – TXCL), a biotechnology company developing innovative, cost-effective, personalized T cell immunotherapies using antigen specific regulatory T-cells (Ag-Tregs) for severe chronic...
Research Insight
TxCell and Ferring partner with Trizell to further develop Ovasave to treat IBD
France-based TxCell and Switzerland's Ferring International have partnered with Trizell Holding to further enhance the development of TxCell's Ovasave to treat inflammatory bowel diseases...
News
Pfizer buys Swiss preclinical stage firm Redvax
Pfizer has purchased a controlling stake in Redvax, a spin-off from Swiss biopharmaceutical firm Redbiotec. Terms of the transaction were not...
Research Insight
Novartis, Intellia and Caribou to develop new medicines and drug discovery tools
Swiss drug-maker Novartis has entered collaboration and licensing agreements with Intellia Therapeutics to develop new medicines using CRISPR genome editing technology and Caribou Biosciences...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from up to 5 devices at once
Must read